GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » Debt-to-Asset

APLIF (Appili Therapeutics) Debt-to-Asset : 4.50 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics Debt-to-Asset?

Appili Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $6.71 Mil. Appili Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.62 Mil. Appili Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $1.63 Mil. Appili Therapeutics's debt to asset for the quarter that ended in Jun. 2024 was 4.50.


Appili Therapeutics Debt-to-Asset Historical Data

The historical data trend for Appili Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics Debt-to-Asset Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Asset
Get a 7-Day Free Trial 0.09 0.06 0.60 2.45 5.49

Appili Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.54 4.09 4.07 5.49 4.50

Competitive Comparison of Appili Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Appili Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Appili Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's Debt-to-Asset falls into.



Appili Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Appili Therapeutics's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Appili Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Appili Therapeutics  (OTCPK:APLIF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Appili Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Appili Therapeutics Business Description

Traded in Other Exchanges
Address
1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.